GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Cyclically Adjusted PB Ratio

Evotec SE (Evotec SE) Cyclically Adjusted PB Ratio : 2.11 (As of Jun. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Cyclically Adjusted PB Ratio?

As of today (2024-06-15), Evotec SE's current share price is $4.55. Evotec SE's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2.16. Evotec SE's Cyclically Adjusted PB Ratio for today is 2.11.

The historical rank and industry rank for Evotec SE's Cyclically Adjusted PB Ratio or its related term are showing as below:

EVO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.1   Med: 11.69   Max: 19.99
Current: 2.1

During the past years, Evotec SE's highest Cyclically Adjusted PB Ratio was 19.99. The lowest was 2.10. And the median was 11.69.

EVO's Cyclically Adjusted PB Ratio is ranked worse than
53.99% of 752 companies
in the Drug Manufacturers industry
Industry Median: 1.865 vs EVO: 2.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Evotec SE's adjusted book value per share data for the three months ended in Mar. 2024 was $3.392. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.16 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evotec SE Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Evotec SE's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Cyclically Adjusted PB Ratio Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.16 15.40 16.86 4.64 5.55

Evotec SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.77 5.08 5.55 3.62

Competitive Comparison of Evotec SE's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Cyclically Adjusted PB Ratio falls into.



Evotec SE Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evotec SE's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.55/2.16
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Evotec SE's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.392/125.0381*125.0381
=3.392

Current CPI (Mar. 2024) = 125.0381.

Evotec SE Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.812 99.543 1.020
201409 0.763 99.823 0.956
201412 0.743 99.543 0.933
201503 0.672 99.717 0.843
201506 0.770 100.417 0.959
201509 0.753 100.417 0.938
201512 0.763 99.717 0.957
201603 0.764 100.017 0.955
201606 0.786 100.717 0.976
201609 0.815 101.017 1.009
201612 0.846 101.217 1.045
201703 1.257 101.417 1.550
201706 1.202 102.117 1.472
201709 1.291 102.717 1.572
201712 1.329 102.617 1.619
201803 1.416 102.917 1.720
201806 1.396 104.017 1.678
201809 1.542 104.718 1.841
201812 1.621 104.217 1.945
201903 1.699 104.217 2.038
201906 1.655 105.718 1.957
201909 1.688 106.018 1.991
201912 1.759 105.818 2.079
202003 1.788 105.718 2.115
202006 1.773 106.618 2.079
202009 1.833 105.818 2.166
202012 2.692 105.518 3.190
202103 2.869 107.518 3.337
202106 3.120 108.486 3.596
202109 3.537 109.435 4.041
202112 4.407 110.384 4.992
202203 4.076 113.968 4.472
202206 3.810 115.760 4.115
202209 3.437 118.818 3.617
202212 3.554 119.345 3.724
202303 0.000 122.402 0.000
202306 3.590 123.140 3.645
202309 3.436 124.195 3.459
202312 3.446 123.773 3.481
202403 3.392 125.038 3.392

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evotec SE  (NAS:EVO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evotec SE Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Evotec SE's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (Evotec SE) Business Description

Industry
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.